JP2013514367A5 - - Google Patents

Download PDF

Info

Publication number
JP2013514367A5
JP2013514367A5 JP2012544740A JP2012544740A JP2013514367A5 JP 2013514367 A5 JP2013514367 A5 JP 2013514367A5 JP 2012544740 A JP2012544740 A JP 2012544740A JP 2012544740 A JP2012544740 A JP 2012544740A JP 2013514367 A5 JP2013514367 A5 JP 2013514367A5
Authority
JP
Japan
Prior art keywords
item
salt according
items
ring
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012544740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013514367A (ja
JP5634526B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/060439 external-priority patent/WO2011084453A1/en
Publication of JP2013514367A publication Critical patent/JP2013514367A/ja
Publication of JP2013514367A5 publication Critical patent/JP2013514367A5/ja
Application granted granted Critical
Publication of JP5634526B2 publication Critical patent/JP5634526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012544740A 2009-12-15 2010-12-15 代謝性疾患を処置するためのppar温存チアゾリジンジオン塩 Active JP5634526B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28676509P 2009-12-15 2009-12-15
US61/286,765 2009-12-15
PCT/US2010/060439 WO2011084453A1 (en) 2009-12-15 2010-12-15 Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases

Publications (3)

Publication Number Publication Date
JP2013514367A JP2013514367A (ja) 2013-04-25
JP2013514367A5 true JP2013514367A5 (enExample) 2013-06-06
JP5634526B2 JP5634526B2 (ja) 2014-12-03

Family

ID=43501294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012544740A Active JP5634526B2 (ja) 2009-12-15 2010-12-15 代謝性疾患を処置するためのppar温存チアゾリジンジオン塩

Country Status (16)

Country Link
US (2) US8912335B2 (enExample)
EP (1) EP2513070B1 (enExample)
JP (1) JP5634526B2 (enExample)
KR (3) KR102029560B1 (enExample)
CN (1) CN102753539B (enExample)
AU (1) AU2010340055B2 (enExample)
CA (1) CA2783468C (enExample)
DK (1) DK2513070T3 (enExample)
ES (1) ES2658168T3 (enExample)
HU (1) HUE038042T2 (enExample)
MX (1) MX2012006725A (enExample)
NO (1) NO2513070T3 (enExample)
NZ (1) NZ600390A (enExample)
PL (1) PL2513070T3 (enExample)
RU (1) RU2564661C2 (enExample)
WO (1) WO2011084453A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5634526B2 (ja) 2009-12-15 2014-12-03 メタボリック ソリューションズ ディベロップメント カンパニー, エルエルシー 代謝性疾患を処置するためのppar温存チアゾリジンジオン塩
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
RU2652783C2 (ru) 2012-12-21 2018-05-03 Санофи Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона
ES2813363T3 (es) * 2013-07-22 2021-03-23 Metabolic Solutions Dev Co Llc Compuestos ahorradores de PPAR para el tratamiento de enfermedades metabólicas
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
WO2019154958A1 (en) 2018-02-08 2019-08-15 Enyo Pharma Use of modulators of neet proteins for the treatment of infection
CN111689934B (zh) * 2020-06-24 2022-08-02 郑州大学 14-脱羟-13-脱氢穿心莲内酯-12-磺酸钾的单晶体及制备方法
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
WO1985004170A1 (fr) 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, leur procede de preparation et compositions medicinales les contenant
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
WO1986002073A1 (fr) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5143930A (en) 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
US5356913A (en) 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
AU1743292A (en) * 1991-04-11 1992-11-17 Takeda Chemical Industries Ltd. Thiazolidinedione derivatives, production and use thereof
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NO318765B1 (no) 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
US7407978B2 (en) 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
AU776162B2 (en) 1999-04-29 2004-08-26 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's)
US6331596B1 (en) 1999-06-28 2001-12-18 Basf Corporation Method of preparing carbamate-functional polymers
DK1192137T3 (da) 1999-06-30 2013-11-11 Amgen Inc Forbindelser til modulering af PPAR-gamma aktivitet
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
JP2004514703A (ja) 2000-12-01 2004-05-20 ノバルティス アクチエンゲゼルシャフト 有機化合物の組合せ剤
PL363738A1 (en) 2001-04-26 2004-11-29 Leciva A.S. Method for obtaining pioglitazone as an antidiabetic agent
AU2002337749A1 (en) 2001-09-28 2003-04-07 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
AUPS236902A0 (en) 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
EP1521753B1 (en) 2002-07-16 2007-09-05 Cadila Healthcare Ltd. A process to prepare pioglitazone via several intermediates.
US20060083784A1 (en) 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
US7230016B2 (en) 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20070078170A1 (en) 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
JP4475983B2 (ja) 2004-03-03 2010-06-09 学校法人日本大学 Bmal1を阻害する方法
RU2430920C2 (ru) 2004-09-28 2011-10-10 Оцука Фармасьютикал Ко., Лтд. Карбостирильное соединение
MX2008011872A (es) 2006-03-16 2009-02-10 Metabolic Solutions Dev Compan Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.
EP2001470A2 (en) * 2006-03-16 2008-12-17 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues
AU2007227581B2 (en) 2006-03-16 2012-11-08 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
AU2008301905B2 (en) 2007-09-14 2013-06-27 Cirius Therapeutics, Inc. Thiazolidinedione analogues for the treatment of hypertension
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
GB2465897B (en) * 2008-08-07 2011-02-09 Argenta Discovery Ltd Respiratory disease treatment
WO2010105048A1 (en) 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues
WO2011017244A1 (en) 2009-08-05 2011-02-10 Metabolic Solutions Development Company Polymorphs of 5-(4-(2-(5-ethylpyridin-2-yl)-2-oxoethoxy)benzyl)-1,3-thiazolidine-2,4-dione (mitoglitazone)
AU2010340061A1 (en) 2009-12-15 2012-06-21 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
JP5634526B2 (ja) 2009-12-15 2014-12-03 メタボリック ソリューションズ ディベロップメント カンパニー, エルエルシー 代謝性疾患を処置するためのppar温存チアゾリジンジオン塩
WO2011084456A1 (en) 2009-12-15 2011-07-14 Metabolic Solutions Development Company Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
EP2512470B1 (en) 2009-12-15 2016-11-30 Octeta Therapeutics, LLC Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
AU2011242844A1 (en) 2010-04-21 2012-11-01 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues

Similar Documents

Publication Publication Date Title
JP2013514367A5 (enExample)
JP2012532848A5 (enExample)
JP2012041349A5 (enExample)
JP2016505614A5 (enExample)
RU2012129930A (ru) Соли тиазолидиндиона со сниженным сродством к ppar для лечения нарушений обмена веществ
JP2011513305A5 (enExample)
JP2016503793A5 (enExample)
JP2013508288A5 (enExample)
IN2014CN00794A (enExample)
JP2014525420A5 (enExample)
JP2016006118A5 (enExample)
JP2011522789A5 (enExample)
JP2013544860A5 (enExample)
JP2014532060A5 (enExample)
JP2013544276A5 (enExample)
JP2016040288A5 (enExample)
JP2014508811A5 (enExample)
RU2007139634A (ru) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
JP2011500550A5 (enExample)
JP2006522035A5 (enExample)
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
JP2011504903A5 (enExample)
JP2011516610A5 (enExample)
JP2015504067A5 (enExample)
JP2007092033A5 (enExample)